Hematology and cell therapy最新文献_第6页

[Ex-vivo expansion of hematopoietic stem cells: study in the primate model]. [造血干细胞的体外扩增:在灵长类动物模型中的研究]。

Hematology and cell therapy Pub Date : 1999-04-01 DOI: 10.1007/s00282-999-0075-x

F Norol, M Drouet, N Debili, W Vainchenker, F Herodin

引用次数: 1

Reticulocytes and solvents: an epidemiological study. 网织红细胞和溶剂:一项流行病学研究。

Hematology and cell therapy Pub Date : 1999-04-01 DOI: 10.1007/s00282-999-0039-1

E Cardoso, J P Cazenave, H Schoch, F Becker, F Conso

{"title":"Reticulocytes and solvents: an epidemiological study.","authors":"E Cardoso, J P Cazenave, H Schoch, F Becker, F Conso","doi":"10.1007/s00282-999-0039-1","DOIUrl":"https://doi.org/10.1007/s00282-999-0039-1","url":null,"abstract":"Objectives: The aim of the study was to look for a rise in reticulocyte levels in workers exposed to various solvents, in comparison to non exposed control subjects.Methods: A cohort of exposed workers was selected on the criterion of exposure to solvents, among employees regularly attending the Centre of Occupational Medicine of Molsheim (France) during the second trimester of 1995. Controls were selected over the same period from the voluntary blood donors of the Transfusion Centre of Strasbourg (France). Complete blood counts and flow cytometric reticulocyte counts were determined in all blood samples.Results: Analysis of the haematological parameters displaying significant differences revealed the existence of higher levels of circulating reticulocytes and lymphocytes in workers exposed to solvents than in control subjects. These variations did not appear to depend on the intensity or length of exposure.Conclusions: This study demonstrates the occurrence of an increase in circulating reticulocytes in relation to occupational exposure to solvents, without as yet providing sufficient information to allow elucidation of the underlying mechanism. An increase in total circulating lymphocytes was observed in the same group of exposed workers. The concomitant rise in absolute values of these two elements of the blood counts is to our knowledge described here for the first time in an epidemiological study.","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0039-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21214369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. 造血祖细胞的体外扩增:乳腺癌的初步结果。

Hematology and cell therapy Pub Date : 1999-04-01 DOI: 10.1007/s00282-999-0082-y

I McNiece, R Jones, P Cagnoni, S Bearman, Y Nieto, E J Shpall

{"title":"Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer.","authors":"I McNiece, R Jones, P Cagnoni, S Bearman, Y Nieto, E J Shpall","doi":"10.1007/s00282-999-0082-y","DOIUrl":"https://doi.org/10.1007/s00282-999-0082-y","url":null,"abstract":"Ex-vivo expanded progenitor cells have been proposed as a source of cells to support high-dose chemotherapy and to decrease or eliminate the period of neutropenia following transplantation. To date, no clinical studies using ex vivo expanded cells, have demonstrated any decrease in the time to neutrophil or platelet recovery, although a number of clinical studies have been performed using a variety of growth factor cocktails and culture conditions. Over the past 6 years we have developed a static culture system that results in optimal expansion of myeloid progenitor cells. We have initiated a clinical study to evaluate this culture system in breast cancer patients receiving peripheral blood progenitor cells (PBPC) to support high-dose chemotherapy. CD34 selected cells were cultured for 10 days in 800 ml of defined media (Amgen Inc.) containing 100 ng/ml each of rhSCF, rhG-CSF and rhMGDF in 1L teflon bags (American Fluoroseal) at 20,000 to 50,000 cells per ml. After culture the cells were washed with 3 volumes of PBS to remove all media and growth factors and reinfused on day 0 of transplant followed by daily administration of rhG-CSF. On day +1 the patients received an unexpanded PBPC product to ensure the durability of the graft. Patients transplanted with expanded PBPC cells recovered neutrophil counts (ANC > 500/microl) as early as day 4 post transplant with a median of 6 days (range 4 to 14 days). In comparison, our historical control group of patients (N=175) had a median time to neutrophil engraftment of 9 days (range 7 to 24 days). A second cohort of patients were transplanted with expanded cells alone and a similar rapid engraftment was obtained. The first patients are now over 70 days post transplant with durable engraftment. No effect on platelet recovery has been observed in any patients to date. These data demonstrate that PBPC expanded under the conditions defined can significantly shorten the time to engraftment of neutrophils.","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0082-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9143464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 35

Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involvement. CD34+外周血祖细胞在低级别淋巴细胞恶性肿瘤和骨髓受累患者中的阳性选择。

Hematology and cell therapy Pub Date : 1999-02-01 DOI: 10.1007/s00282-999-0005-y

F Viret, D Blaise, R Bouabdallah, A M Stoppa, G Novakovitch, C Faucher, N Vey, J Camerlo, S Oziel-Taieb, P Ladaique, J A Gastaut, D Maraninchi, C Chabannon

{"title":"Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involvement.","authors":"F Viret, D Blaise, R Bouabdallah, A M Stoppa, G Novakovitch, C Faucher, N Vey, J Camerlo, S Oziel-Taieb, P Ladaique, J A Gastaut, D Maraninchi, C Chabannon","doi":"10.1007/s00282-999-0005-y","DOIUrl":"https://doi.org/10.1007/s00282-999-0005-y","url":null,"abstract":"Purpose: 16 patients with low-grade lymphoid malignancies and bone marrow involvement were transplanted with selected CD34 positive Peripheral Blood Progenitor Cell (PBSC) prepared from autologous aphereses.Patient and methods: All but one patients were mobilized with a combination of chemotherapy (including high-dose cyclophosphamide and VP16 or adriamycin, aracytin with cysplatyl) and recombinant human Granulocyte Colony-Stimulating Factor (rhG-CSF).Results: A median of 3 (range, 1 to 9) aphereses yielded 15.35 x 10(6) CD34+ cells/kg (range, 4.45 to 70.88). A median of 5.01 x 10(6) adsorbed CD34+ cells/kg (range 2.01 to 24.13) was obtained after selection (median purity: 86%; range, 59-99%). The CD34 PBSC were infused one day after either one of two conditioning regimens: 11 patients received the association of cyclophosphamide (120 mg/kg) and TBI (8Gy), and 5 patients received the BEAM regimen. No recombinant hematopoietic growth factor was used after cell reinfusion. Median days to 0.5 x 10(9)/l neutrophils and 50 x 10(9)/l platelets were 13 (range, 9 to 18) and 16 (range, 11 to 35), respectively. The median number of red blood cell (RBC) unit transfusions was 4 (range, 0 to 10). The median number of platelet transfusions was 3.5 (range, 0 to 8). No individual received backup PBSC, nor required platelet transfusion beyond 3 months post-transplant.Conclusion: This study confirms the feasability of using blood CD34 cells to support hematopoietic recovery after myelo-suppressive or myelo-ablative regimens, in patients with low-grade NHL.","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0005-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21064849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). B型慢性淋巴细胞白血病(CLL)微小残留病的检测。

Hematology and cell therapy Pub Date : 1999-02-01 DOI: 10.1007/s00282-999-0013-y

C Magnac, L Sutton, B Cazin, C Laurent, J L Binet, H Merle-Béral, G Dighiero, K Maloum

{"title":"Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL).","authors":"C Magnac, L Sutton, B Cazin, C Laurent, J L Binet, H Merle-Béral, G Dighiero, K Maloum","doi":"10.1007/s00282-999-0013-y","DOIUrl":"https://doi.org/10.1007/s00282-999-0013-y","url":null,"abstract":"Unlabelled: In the absence of specific chromosomal translocations the best method for detecting minimal residual disease (MRD) in B cell malignancies is based on the uniqueness of immunoglobulin (Ig) genes rearrangement. We here report a very sensitive method for assessing MRD in complete hematological remission (CHR) chronic lymphocytic leukemia (CLL) patients as defined by the international workshop on CLL (IWCLL).Patients: Twelve CLL patients in CHR and complete phenotypic remission (CPR) were included in the study. Eight of them received Fludarabine (FDR), one was treated by Chop regimen, and the remaining 3 were rescued by polychemotherapy followed by autologous bone marrow transplantation (ABMT).Methods: DNA extracted from peripheral blood lymphocytes (PBL) of each patient was amplified with VH family specific and framework 3 primers in 5' and a consensus JH primer in 3', before treatment and sequentially after the CPR completion. When no clonal rearrangement could be detected by this assay, the CDR3 sequence specific probe of the clone was used as the 3' primer, associated to the VH family specific primer in 5'. PCR products were analyzed by classical procedures in agarose and/or acrylamide gels.Results: Mixtures of leukemic cells and normal PBL showed detection of a single leukemic cell among more than 10(5) normal cells. Four out of the 12 patients achieved molecular remission (MR) when employing CDR3 amplification. All 3 autografted patients were in MR, whereas only one out of the 9 patients treated by chemotherapy alone achieved MR. When using a clone specific probe, a clonal signal was observed in all cases but one (ABMT). Results presented here confirm that MR may be achieved in a few cases of B-CLL. Further studies are needed to determine the exact relationship between MRD and clinical outcome.","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0013-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21064850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 29

Pure red cell aplasia evolving through the hyperfibrotic myelodysplastic syndrome to the acute myeloid leukemia: some pathogenetic aspects. 纯红细胞发育不全，从增生性骨髓增生异常综合征发展到急性髓性白血病:一些发病方面。

Hematology and cell therapy Pub Date : 1999-02-01 DOI: 10.1007/s00282-999-0027-5

N Suvajdzic, D Marisavljevic, V Jovanovic, M Pantic, D Sefer, M Colovic

{"title":"Pure red cell aplasia evolving through the hyperfibrotic myelodysplastic syndrome to the acute myeloid leukemia: some pathogenetic aspects.","authors":"N Suvajdzic, D Marisavljevic, V Jovanovic, M Pantic, D Sefer, M Colovic","doi":"10.1007/s00282-999-0027-5","DOIUrl":"https://doi.org/10.1007/s00282-999-0027-5","url":null,"abstract":"The authors report a 58-year-old female who originally presented with acquired pure red cell aplasia (PRCA). At diagnosis, the karyotype was normal, the serum erythropoietin level was highly elevated and no T-cell mediated inhibition of erythropoiesis was demonstrated in coculture studies. Conventional immunosuppressive therapy proved ineffective. A year later a diagnosis of hyperfibrotic myelodysplastic syndrome was assessed. The sequential bone marrow examinations in the course of the three years showed a progressive increase in bone marrow fibrosis, erythroid hyperplasia and dysmegakaryocytopoiesis, terminating in the acute myeloid leukemia. This sequence of the events included the appearance of del(5)(q13q33), four years after setting a diagnosis of PRCA. The authors suggest that the absence of both cytogenetic abnormality and the signs of dyshematopoiesis at the diagnosis of PRCA does not exclude ultimately a \"clonal\" category of the disease. Thus, repeated hematological and cytogenetical reevaluations are recommended.","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0027-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21065371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Leukocyte recovery from umbilical cord blood by poligeline. 从脐带血中提取白细胞。

Hematology and cell therapy Pub Date : 1999-02-01 DOI: 10.1007/s00282-999-0001-2

P Perutelli, S Catellani

{"title":"Leukocyte recovery from umbilical cord blood by poligeline.","authors":"P Perutelli, S Catellani","doi":"10.1007/s00282-999-0001-2","DOIUrl":"https://doi.org/10.1007/s00282-999-0001-2","url":null,"abstract":"Umbilical cord blood (UCB) collected at delivery is a source of transplantable stem/progenitor cells; it represents an alternative to bone marrow to restore hematopoiesis in patients affected by malignant and non-malignant disease. Therefore, large-scale UCB banks would be a natural complement to bone marrow donor registries. Storage of unmanipulated whole UCB units requires a great number of liquid nitrogen containers. Separation of leukocytes allows UCB storage in smaller space, thus lowering banking costs; unfortunately, UCB processing may cause significant losses of stem cells. We report about the use of poligeline to remove erythrocytes from UCB units. After erythrocyte sedimentation at 1xg (30' or 40') or 50xg, leukocyte-rich supernatant was collected and centrifuged to recover the leukocyte pool in view of stem cell transplantation. Erythrocyte depletion was always satisfactory, ranging from 82.6% to 88.9%, but 1xg sedimentation for 40' enabled us to achieve the best CD34+ cell recovery (mean value 80.5%). The proposed UCB-processing method allowed us to lower the final sample volume down to 1/10 of the initial one, in this way making UCB banking feasible. Erythrocyte depletion took place directly in the collection bag, thus reducing microbial contamination risk.","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0001-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21064848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Hypermethylation of calcitonin gene in adult acute leukemia at diagnosis and during complete remission. 成人急性白血病诊断时和完全缓解期间降钙素基因的高甲基化。

Hematology and cell therapy Pub Date : 1999-02-01 DOI: 10.1007/s00282-999-0019-5

X Thomas, M H Teillon, A Belhabri, R Rimokh, D Fiere, J P Magaud, E Archimbaud

{"title":"Hypermethylation of calcitonin gene in adult acute leukemia at diagnosis and during complete remission.","authors":"X Thomas, M H Teillon, A Belhabri, R Rimokh, D Fiere, J P Magaud, E Archimbaud","doi":"10.1007/s00282-999-0019-5","DOIUrl":"https://doi.org/10.1007/s00282-999-0019-5","url":null,"abstract":"Hypermethylation of the calcitonin gene has been described in various hematologic malignancies. In order to assess its frequency and potential usefulness as a marker for leukemic cells and to detect potential clinical correlations, 180 adult patients (aged > 15 years) with newly diagnosed acute leukemia including 133 cases of acute myeloid leukemia (AML) and 47 cases of acute lymphoblastic leukemia (ALL) were tested for its presence in leukemic blasts at diagnosis by Southern blot technique and polymerase chain reaction (PCR) using 3 sets of primers (P550, P566, P1400), amplifying the most frequent sites of hypermethylation upstream or within the gene. In AML, 92 patients (69%) had hypermethylation detected by Southern blot at diagnosis. This hypermethylation could be confirmed by PCR in 18 of 36 tested cases (50%). Hypermethylation was not significantly associated to any clinical or hematological characteristic of the disease. In ALL, 44 patients (94%) had hypermethylation detected by Southern blot at diagnosis. This hypermethylation could be confirmed by PCR in 33 of the 43 tested cases (77%). Sensitivity of PCR assessed by dilution was 1 to 0.1%. Hypermethylation was not either significantly related to any clinical or hematologic characteristics of the disease. Seven ALL cases which were positive by PCR at diagnosis and achieved cytological CR could be tested during CR. Five cases were negative and did not relapse after 3 to 27 months in CR. One case was positive at the beginning of CR and became negative after autologous transplant. However, he relapsed after 9 months in CR, 3 months after the last negative test. PCR for Bcr/Abl was also negative at this time. We conclude that hypermethylation of the calcitonine gene is frequent at diagnosis in adult acute leukemia, particularly in ALL.","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0019-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21065370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

A case report: CD8 expression in B-cell chronic lymphocytic leukemia (B-CLL). Prognostic significance of the aberrant CD8 expression. CD8在b细胞慢性淋巴细胞白血病(B-CLL)中的表达1例。CD8异常表达的预后意义。

Hematology and cell therapy Pub Date : 1998-12-01

C Brunet, N Bardin, O Oukhouya, J R Harlé, H Zattara-Cannoni, F Dignat-George, J Sampol

{"title":"A case report: CD8 expression in B-cell chronic lymphocytic leukemia (B-CLL). Prognostic significance of the aberrant CD8 expression.","authors":"C Brunet, N Bardin, O Oukhouya, J R Harlé, H Zattara-Cannoni, F Dignat-George, J Sampol","doi":"","DOIUrl":"","url":null,"abstract":"The human CD8 molecule is usually expressed on T lymphocytes or natural killer cells but not on normal B cells. Over a course of 5 years, we followed a case of B-CLL which aberrantly expressed the CD8 molecule. During this period, the clinical and hematological conditions of the patient were stable. This B-CLL presented a typical immunophenotype (HLA DR+, CD19+, CD5+, CD23+) with monotypic expression of surface immunoglobulin light chain kappa. We confirmed the CD8 expression on these leukemia cells by using double labelling and different antibodies directed against this antigen. We measured the quantitative expression of the CD8 molecule. The number of CD8 molecules per cell was clearly lower on these malignant B cells than on normal T lymphocytes. In order to evaluate the prognostic significance of this CD8 expression, we quantitated in parallel other markers such as CD5, CD23, CD22, CD11c. During 5 years, this aberrant CD8 expression persisted and was associated with an increase of the CD23 and a decrease of CD22 levels, known to correlate with a good prognosis in agreement with the karyotype analysis. Altogether our results led us to conclude that the aberrant CD8 expression in this case of B-CLL may correlate with a non-aggressive form of lymphoproliferative disorder.","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1998-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20830870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative analysis of class I, II and III epitope-detecting CD34 monoclonal antibodies by quantitative flow cytometry. 流式细胞术检测ⅰ、ⅱ、ⅲ类CD34单克隆抗体表位的比较分析。

Hematology and cell therapy Pub Date : 1998-12-01

H Sovalat, E Racadot, P Hénon, P Fuchs, H Lewandowski, M Billot

{"title":"Comparative analysis of class I, II and III epitope-detecting CD34 monoclonal antibodies by quantitative flow cytometry.","authors":"H Sovalat, E Racadot, P Hénon, P Fuchs, H Lewandowski, M Billot","doi":"","DOIUrl":"","url":null,"abstract":"Unlabelled: The aim of this study was to compare different CD34 monoclonal antibodies (MAbs) belonging to three different classes: MY10 class I, QBend10 class II, a mixture of three selected MAbs class I and II designated as CD34 Pool, and 8G12 class III. Bone marrow (BM) samples from 13 healthy donors were analyzed for: 1) percentage of CD34+ cells, 2) quantitative expression of CD34 epitopes (antigen's density - AgD) using a quantitative indirect immunofluorescence (QIFI) test, 3) study of CD34+ cell subsets defined by CD34 and CD38 coexpression. 8G12 MAb showed the highest reactivity with regard to the percentage of detected CD34+ cells and AgD on these cells. A nearly identical percentage of CD34+ cells was detected with CD34 Pool, but with a lower AgD. With QBend10, the percentage of CD34 expressing cells was insignificantly decreased and the AgD was slightly lower. The expression of the MY10 epitope was the lowest and was detected on the lowest number of CD34+ cells. Concerning CD34 and CD38 coexpressing subset, we observed that 8G12 class III MAb detected CD34loCD38dim cells with comparable efficiency with MY10 class I MAb, but with significantly higher level than QBend10 class II and CD34 Pool class I+II MAbs. The CD34hiCD38dim subset was detected with the same efficiency by QBend10, CD34 Pool or 8G12 MAbs but with significantly higher frequency than MY10 MAb.In conclusion: class II and III MAbs appear preferable for flow cytometric quantification of CD34+ cells; for CD34+ cell subsets determination class III MAbs should be suitable.","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1998-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20830867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0